IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma - Slideshow

IDEAYA Biosciences presented topline results from its OptimUM-02 trial evaluating darovasertib combined with crizotinib for HLA-A2-negative metastatic uveal melanoma, a rare and aggressive cancer with limited treatment options. The Phase 2 trial assessed the combination therapy’s efficacy and safety, targeting a patient population with historically poor responses to existing therapies. Early data suggest potential clinical benefit, though full results remain pending. Key endpoints included objective response rate, progression-free survival, and overall survival, with preliminary findings indicating encouraging tumor response rates compared to standard care. The company highlighted the trial’s design, which leverages darovasertib’s PKCi inhibition and crizotinib’s MET/ALK/ROS1 targeting to disrupt tumor growth pathways in this genetically distinct melanoma subtype. Investor and clinical interest centers on whether these results could support accelerated regulatory pathways or partnerships, given the unmet need in this niche oncology indication.